🚀 PS launches takeover of Universal Music Group

In partnership with

Market Overview
Read time 1.4 minutes

Year To Date Performances:

1. Bill Ackman’s Pershing Square has launched a massive $64.4 billion bid to acquire Universal Music Group (UMG) and move its primary listing from Amsterdam to the New York Stock Exchange. Under the terms of the cash-and-stock proposal, UMG shareholders would receive $10.85 billionin cash along with 0.77 shares of a newly formed company for every share they currently hold. This offer represents a significant 78% premium over UMG's closing price on April 2, valuing the company at roughly $35 per share. Ackman argues that while the label, home to stars like Taylor Swift and Lady Gaga, is a world-class business, its stock price has "languished" due to structural issues, including the postponement of its U.S. listing and uncertainty surrounding the Bollore Group’s 18% stake.

2. Seven House Democrats, led by Massachusetts Representatives Jim McGovern and Seth Moulton, have called on the Commodity Futures Trading Commission (CFTC) to crack down on "corrupt" offshore prediction market bets involving war and government actions. In a letter sent to CFTC Chair Michael Selig, lawmakers highlighted suspicious, well-timed wagers on the U.S. attack on Iran and the attempted ouster of Nicolas Maduro, raising serious allegations of insider trading on platforms like the offshore-based Polymarket. The inquiry specifically questions whether the CFTC is investigating potential conflicts of interest involving "family members of Executive Branch officials," noting that Donald Trump Jr. serves as an advisor to both Polymarket and the U.S.-regulated platform Kalshi. While the CFTC has recently sparred with state regulators to assert federal authority over these markets, the lawmakers are demanding a formal response by April 15 on why the agency hasn't applied existing prohibitions against betting on assassinations, terrorism, and war to these rapidly growing platforms.

3. Novo Nordisk’s launch of the oral Wegovy pill has triggered a massive expansion of the obesity treatment market, securing over 600,000 prescriptions within its first three months by targeting patients who previously avoided GLP-1 therapy due to needle phobias or high costs. Early data suggests the pill is successfully drawing in a new wave of users rather than cannibalizing the existing injection market, fueled by an aggressive entry price of $149 to $299 USD per month. While the pill offers a convenient alternative for the estimated 25% of U.S. adults who fear needles, it faces looming competition from Eli Lilly’s recently approved pill, Foundayo, which may appeal to users seeking to avoid the strict dietary requirements associated with Novo’s oral formulation. Despite the explosive patient uptake, Novo’s stock has remained largely flat as investors wait for May’s first-quarter earnings report to see if the projected $2.76 billion USD in annual pill revenue can help the company reclaim market dominance from Lilly.

   Headlines

   1. Trump finalizes Medicare Advantage payment rate, increasing it by 2.48%.

   2. The US housing market is dipping due to the war in Iran, causing economic uncertainty.